We profiled 5,612 high-quality cells at diagnosis and relapse from 6 AML patients, two intermediate risk cases with t(8;21) (AML1-ETO), three DNMT3A and one NUP98/NSD1. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.